Peptide YY3-36 intranasal - Marina Biotech

Drug Profile

Peptide YY3-36 intranasal - Marina Biotech

Alternative Names: Peptide YY3-36 intranasal; Peptide YY3-36 nasal spray; PYY3-36 intranasal; PYY3-36 nasal spray

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator Thiakis
  • Developer Marina Biotech
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Neuropeptide Y2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 25 Aug 2010 Marina Biotech is seeking to divest its nasal drug delivery programmes
  • 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech
  • 01 Aug 2008 Efficacy and adverse events data from a phase II trial in Obesity released by MDRNA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top